Pivoting to GLP-1 RAs, Soung explained that they both decrease appetite and food cravings and are very different from the weight loss drugs of the past in terms of how they work, the fact that they ...
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that would solidify the companies’ existing ...
Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla ...
Amgen Inc on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis medication Otezla, bucking challenges from lower ...
A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...
Dr Kaywaan Khan says benefits have been found in illnesses such as lupus as well as in heart and kidney health ...
Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...
Colorado became the first state in the nation to set a price cap on a specific medication last week, following a unanimous ...
A 16-week Mediterranean diet intervention significantly improved psoriasis severity and metabolic health in adults with mild to moderate psoriasis. The study demonstrated a notable reduction in ...
Dr Philip Mease explores how modern imaging tools are reshaping the understanding of joint damage and progression in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback